HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: A multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2550-2557

  Oehler Jänne, Christoph ^b   Huguet, Florence ^b   Provencher, Sawyna ^b   Seifert, Burkhardt ^b   Negretti, Laura ^b   Riener, Marc Oliver ^b   Bonet, Marta ^b   Allal, Abdelkarim S ^b   Ciernik, I Frank ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CISPLATIN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FLUOROPYRIMIDINE; FLUOROURACIL; INDINAVIR; LAMIVUDINE; LOPINAVIR; MITOMYCIN; NELFINAVIR; NEVIRAPINE; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ANUS CARCINOMA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIATION ENTEROPATHY; RETROSPECTIVE STUDY; SEX RATIO; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; ANUS TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 45149113332     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.2348     Document Type: Article

References (40)

1. UNAIDS: Global Summary of the HIV and AIDS Epidemic. http://www.unaids. org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default.asp
2. Bower M, Powles T, Newsom-Davis T, et al: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 37:1563-1565, 2004
3. Melbye M, Cote TR, Kessler L, et al: High incidence of anal cancer among AIDS patients: The AIDS/Cancer Working Group. Lancet 343:636-639, 1994
4. Goedert JJ: The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 27:390-401, 2000
5. Chiao EY, Krown SE, Stier EA, et al: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 40:451-455, 2005
6. Bhaskaran K, Brettle R, Porter K, et al: Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: Incidence and predictors. Aids 18:673-681, 2004
7. Heard I, Palefsky JM, Kazatchkine MD: The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 9:13-22, 2004
8. Survival after introduction of HAART in people with known duration of HIV-1 infection: The CASCADE Collaboration - Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 355:1158-1159, 2000
9. Chiao EY, Giordano TP, Palefsky JM, et al: Screening HIV-infected individuals for anal cancer precursor lesions: A systematic review. Clin Infect Dis 43:223-233, 2006
10. Bonnet F, Lewden C, May T, et al: Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 101:317-324, 2004
11. Flam M, John M, Pajak TF, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14:2527-2539, 1996
12. Sparano JA, Wiernik PH, Hu X, et al: Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 15:50-57, 1998
13. Pajonk F, Himmelsbach J, Riess K, et al: The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62:5230-5235, 2002
14. Antoniou T, Tseng AL: Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44:111-145, 2005
15. Diamond C, Taylor TH, Im T, et al: Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol 24:139-145, 2006
16. Bearz A, Vaccher E, Spazzapan S, et al: Lung cancer in 61 HIV-infected patients: A pre- and post-HAART era analysis. Int Conf AIDS B10608, 2004
17. Blazy A, Hennequin C, Gornet JM, et al: Anal carcinomas in HIV-positive patients: High-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 48:1176-1181, 2005
18. Allen-Mersh T, Hanna-Morris AJ, Goldstone SE, et al: Is chemoradiation the treatment of choice for anal squamous cell carcinoma developing in HIV-positive patients with access to highly active antiretroviral therapy? ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 22-24, 2004 (abstr 233)
19. Kinsella TJ, Kinsella MT, Reynolds H, et al: Comparable tumor response and acute/late normal tissue toxicities with standard combined modality treatment for anal squamous cell carcinomas in HIV-positive and HIV-negative patients. Int J Radiat Oncol Biol Phys 63:S16, 2005
20. Mathieu N, Aparicio T, Roudot-Thoraval F, et al: Comparison of squamous cell carcinoma of the canal anal (SCCA) prognosis in patients infected or not by human immunodeficiency virus (HIV). J Clin Oncol 25:230s, 2007 (suppl; abstr 4632)
21. Oehler-Jänne C, Seifert B, Lütolf UM, et al: Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol 1:29, 2006
22. Oehler-Jänne C, Seifert B, Lutolf UM, et al: Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 6:218-226, 2007
23. Grandhi J, Philip PA, Washington T, et al: A retrospective review of anal squamous cell carcinoma in HIV positive and HIV negative patients. J Clin Oncol 24:215s, 2006 (suppl; abstr 4153)
24. Bartelink H, Roelofsen F, Eschwege F, et al: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040-2049, 1997
25. Goldman S, Glimelius B, Glas U, et al: Management of anal epidermoid carcinoma: An evaluation of treatment results in two population-based series. Int J Colorectal Dis 4:234-243, 1989
26. Johnson LG, Madeleine MM, Newcomer LM, et al: Anal cancer incidence and survival: The surveillance, epidemiology, and end results experience, 1973-2000. Cancer 101:281-288, 2004
27. Allal AS, Mermillod B, Roth AD, et al: The impact of treatment factors on local control in T2-T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Cancer 79:2329-2335, 1997
28. Weber DC, Kurtz JM, Allal AS: The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 50:675-680, 2001
29. Graf R, Wust P, Hildebrandt B, et al: Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 65:14-22, 2003
30. Constantinou EC, Daly W, Fung CY, et al: Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 39:651-657, 1997
31. Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin - UKCCCR Anal Cancer Trial Working Party: UK Co-ordinating Committee on Cancer. Lancet 348:1049-1054, 1996
32. Bosset JF, Roelofsen F, Morgan DA, et al: Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas: Results of a phase II study of the European Organization for Research and Treatment of Cancer - Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 39:45-51, 2003
33. Cummings BJ, Keane TJ, O'Sullivan B, et al: Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 21:1115-1125, 1991
34. Das P, Crane CH, Ajani JA: Current treatment for localized anal carcinoma. Curr Opin Oncol 19:396-400, 2007
35. Ajani JA, Winter KA, Gunderson LL, et al: Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol 24:180s, 2006 (suppl; abstr 4009)
36. James R, Meadows H, Wan S: ACT II: The second UK phase III anal cancer trial. Clin Oncol (R Coll Radiol) 17:364-366, 2005
37. Salama JK, Mell LK, Schomas DA, et al: Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience. J Clin Oncol 25:4581-4586, 2007
38. Wrangle JM, Khuri FR: Chemoprevention of squamous cell carcinoma of the head and neck. Curr Opin Oncol 19:180-187, 2007
39. Choe MS, Zhang X, Shin HJ, et al: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4:1448-1455, 2005
40. Chiao EY, Giordano TP, Richardson P, et al: Human immunodeficiency virus-associated squamous cell cancer of the anus: Epidemiology and outcomes in the highly active antiretroviral theapy era. J Clin Oncol 26:474-479, 2008